\
&
Contact us
\
&
Contact us
Starts in 1 month from now
LocationHybrid, Brussels and online
ProgrammesThe event organised in the context of the European Virtual Human Twins Initiative will mark the launch of an €24 million advanced platform for virtual human twins modeling, integration, and validation. It addresses stakeholders from across Europe, including researchers, healthcare professionals, industry innovators, policymakers, and Member State authorities, to discuss the way forward, particularly how to accelerate the integration and uptake of VHT technologies and to further shape the strategic vision of the European Virtual Human Twins Initiative.
A draft agenda is available here.
To register to attend in person, please use the following link here.
For further information or questions, please reach out to cnect-EU-VHT-INITIATIVE@ec.europa.eu.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
